Loading...
Printed on 7/21/2026
For informational purposes only. This is not medical advice.
The ECog-12 is a short informant questionnaire assessing decline in cognitively mediated everyday activities such as memory, language, and executive function. Items are scored from 1 to 4, and the mean score is commonly used for interpretation, with higher values indicating greater decline.
Formula: ECog-12 mean score = total score / 12 (mean range 1.0-4.0).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
The ECog-12 is an informant-rated questionnaire completed by a close family member or caregiver who has regular, direct contact with the patient. The 12 items span multiple cognitively mediated everyday activity domains: memory (e.g., remembering a short list, recalling recent events), language (e.g., finding the right word, following a conversation), visuospatial ability (e.g., finding objects around the house, following a map), planning (e.g., planning a sequence of errands, organizing activities), organization (e.g., keeping track of finances, organizing belongings), and divided attention (e.g., managing multiple tasks simultaneously). Each item asks the informant to compare the patient's CURRENT performance to their performance 10 years ago.
Each of the 12 items is scored 1 to 4: 1 = better or no change compared to 10 years ago; 2 = occasionally worse; 3 = consistently a little worse; 4 = consistently much worse. A score of 1 on all 12 items (total = 12) indicates no perceived decline — the informant perceives no deterioration in any everyday cognitive activity. A score of 4 on all items (total = 48) indicates consistently much worse performance across all domains. Items are scored based on actual observed performance in real-life settings, not on what the patient could do in a testing environment.
Calculate the ECog-12 mean score = total score / 12. The mean score ranges from 1.0 (no decline perceived) to 4.0 (consistently much worse across all domains). A mean score of 1.0 to 1.5 is generally considered within normal variation. A mean score above approximately 2.0 is often used as a threshold for clinically meaningful informant-reported decline, though validated thresholds vary across studies. Higher mean scores are associated with greater likelihood of MCI and dementia on objective cognitive testing. Serial ECog-12 measurements track trajectory of perceived functional cognitive decline over time.
Memory clinic physicians, geriatric psychiatrists, neurologists, neuropsychologists
The ECog-12 provides collateral informant-based evidence of everyday cognitive decline that complements objective cognitive testing (MMSE, MoCA, neuropsychological assessment). Patients with Alzheimer's disease typically have high ECog-12 scores reported by informants, often exceeding objective test scores due to the patient's anosognosia. The ECog-12 is particularly valuable for patients who perform near-ceiling on brief cognitive screens despite significant subjective complaints — informant ECog-12 data provides objective evidence of real-world cognitive impact. In memory clinic practice, combining ECog-12 with the [Pfeffer FAQ](/tools/pfeffer-faq) provides complementary informant-based cognitive and functional profiles.
Dementia researchers, clinical trialists, neuropsychologists
The ECog-12 shows good discrimination between cognitively normal older adults and those with MCI or Alzheimer's dementia in research settings, with area under the ROC curve values of 0.75 to 0.85 in published validation studies. Its multi-domain coverage (memory, language, visuospatial, executive) captures the breadth of everyday cognitive decline better than single-domain informant tools. In clinical trials, ECog-12 is used as an ecological validity measure — documenting that observed changes in objective cognitive tests translate to meaningful real-world functional cognitive change visible to caregivers.
Geriatricians, memory clinic teams, social workers, care coordinators
The ECog-12 formally captures the caregiver's perspective on everyday cognitive changes in a standardized, quantifiable way. This perspective is clinically essential because caregivers observe hundreds of daily cognitive challenges that are invisible in brief clinic visits. Elevated ECog-12 scores — even when objective cognitive testing is near-normal — validate caregiver concerns, reduce caregiver-patient conflict about the reality of cognitive change, and support caregiver access to support services. The ECog-12 total and item profile can be shared with families to demonstrate that their observations have been formally documented and taken seriously.
Memory clinic physicians, research coordinators, geriatricians
Serial ECog-12 administration documents informant-perceived cognitive trajectory over time in patients with MCI and early dementia. Rising ECog-12 scores validate the clinical impression of progressive decline, support treatment decisions, and document disease progression for clinical trial participation assessments. The ECog-12 is sensitive to detecting early-stage changes that may precede significant objective cognitive test score changes, making it potentially useful for identifying patients who are transitioning from subjective cognitive decline to MCI stages.
Clinical researchers, occupational therapists, rehabilitation teams
Objective cognitive test score improvements after cognitive rehabilitation or pharmacological intervention may not translate to improvements in everyday cognitive function. The ECog-12 provides a standardized measure of whether cognitive changes observed in the clinic translate to meaningful improvements in daily cognitive activities visible to caregivers. Using ECog-12 as an ecological validity measure alongside objective cognitive outcomes provides a more complete picture of intervention benefit. Reduction in ECog-12 scores after intervention documents that the patient is perceived as functioning better in everyday cognitive activities.
The ECog-12 specifically asks informants to compare the patient's CURRENT performance to their performance 10 YEARS AGO — not to their last visit or recent clinical assessment. This 10-year reference point is important because it standardizes the comparison window across patients and captures the long-term trajectory of cognitive change. When completing the tool, explicitly remind the informant: 'I want you to think about how [patient name] managed these everyday activities 10 years ago, and compare that to how they manage them today.'
The ECog-12 (Everyday Cognition Scale, 12-item short form) assesses INFORMANT-RATED EVERYDAY COGNITIVE DECLINE and is a dementia-focused tool. It is completely different from the ECOG Performance Status (Eastern Cooperative Oncology Group scale, 0 to 4) used in oncology. These two tools share similar abbreviations but measure entirely different constructs. Never confuse them — using ECOG Performance Status interpretation for an ECog-12 score would be a serious clinical error.
While validated thresholds vary, a mean ECog-12 score above 2.0 — indicating that the informant perceives the patient as 'occasionally worse' or more across multiple everyday cognitive domains — is generally considered clinically meaningful. At this level, comprehensive cognitive assessment, functional evaluation, and clinical history review are indicated. Mean scores above 3.0 indicate consistently much worse performance across multiple domains and are strongly associated with dementia-range impairment on objective testing.
The ECog-12 covers multiple cognitive domains — memory, language, visuospatial, planning, organization, and divided attention. Examining the item-level profile alongside the mean score provides domain-specific information. If memory items (especially delayed recall of a short list) are prominently elevated while other domains are relatively spared, this suggests an amnestic syndrome characteristic of Alzheimer's disease. If executive/planning and language items are prominently elevated, consider non-amnestic MCI or frontotemporal dementia. The profile guides the focus of subsequent objective neuropsychological testing.
ECog-12 scores are most reliable when the informant has frequent, direct daily contact with the patient. An informant who sees the patient only weekly or monthly will have less opportunity to observe daily cognitive challenges and may systematically underestimate decline. Always document informant relationship and contact frequency. If the primary caregiver is not available, the next-most-knowledgeable informant should complete the scale, with a note about their contact frequency and relationship.
When patients present with subjective cognitive decline (SCD) — complaints of memory or cognitive decline not confirmed by objective testing — the ECog-12 provides a way to evaluate whether informants observe real-world changes consistent with the complaint. A patient with SCD and low ECog-12 (informant perceives no change) has a different risk profile and management trajectory than one with SCD and high ECog-12 (informant confirms the complaints). Informant confirmation of subjective complaints substantially increases the predictive value for future cognitive decline.
The Pfeffer FAQ assesses IADL functional performance (does the patient successfully complete daily tasks?). The ECog-12 assesses the COGNITIVE QUALITY of everyday task performance (does the patient's thinking and memory function as well as before?). These are complementary — a patient may still complete IADLs successfully (FAQ relatively preserved) but do so less efficiently, with more effort, and with more cognitive errors (ECog-12 elevated). Using both tools together provides a more complete picture of cognitive-functional status than either alone.
The ECog-12 measures informant-perceived trajectory — it is inherently a change measure. A single ECog-12 assessment provides limited information about the patient's current absolute cognitive function. Serial assessments at 6 to 12 month intervals are most clinically informative, documenting whether the informant perceives cognitive decline is stable, progressing, or improving. A consistently rising ECog-12 across 2 to 3 serial assessments provides more confidence in a progressive decline trajectory than any single measurement.
ECog-12 was developed as a psychometrically strong short form of the ECog and has continued validation for cognitive-impairment discrimination.
Higher ECog-12 means indicate greater informant-reported everyday cognitive decline.
Use when an informant is available and clinicians need collateral functional-cognition context in dementia evaluation.
Informant bias and varying patient contact can influence results; interpret together with objective and clinical findings.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Assess instrumental daily-function impairment with the 10-item Pfeffer FAQ (0-30).
OpenGeriatricsEstimate informant-reported cognitive decline using the short 16-item IQCODE mean score.
OpenGeriatricsScreen for cognitive impairment using the 8-item AD8 informant interview (score 0-8).
OpenGeriatricsClassify dementia severity with the Clinical Dementia Rating global stage (0, 0.5, 1, 2, 3).
Open